We narrowed to 223 results for: Kars

1. pAAV-nEF-Con/Foff 2.0-ChRmine-oScarlet (AAV8)

   Viral Prep

   #137161-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChRmine-oScarlet (#137161). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChRmine-oScarlet plasmid DNA. nEF-driven expression of ChRmine-oScarlet in the presence of Cre (inhibited in the presence of Flp). These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   nEF

   Tags

   oScarlet (Cre-dependent)

   Available since

   Oct. 14, 2020

   Availability

   Academic Institutions and Nonprofits only

2. pAAV-nEF-Coff/Fon-Arch3.3-p2a-EYFP (AAV8)

   Viral Prep

   #137150-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-nEF-Coff/Fon-Arch3.3-p2a-EYFP (#137150). In addition to the viral particles, you will also receive purified pAAV-nEF-Coff/Fon-Arch3.3-p2a-EYFP plasmid DNA. nEF-driven, Flp-dependent expression of Arch3.3-EYFP (inhibited in presence of Cre) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   nEF

   Tags

   EYFP (Flp-dependent)

   Available since

   May 5, 2021

   Availability

   Academic Institutions and Nonprofits only

3. pAAV-nEF-Con/Fon-Arch3.3-p2a-EYFP (AAV8)

   Viral Prep

   #137148-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-Arch3.3-p2a-EYFP (#137148). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-Arch3.3-p2a-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of Arch3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   nEF

   Tags

   EYFP (Cre and Flp-dependent)

   Available since

   May 6, 2021

   Availability

   Academic Institutions and Nonprofits only

4. pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP (AAV8)

   Viral Prep

   #137149-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP (#137149). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-Arch3.3-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of Arch3.3-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   nEF

   Tags

   EYFP (Cre-dependent)

   Available since

   May 6, 2021

   Availability

   Academic Institutions and Nonprofits only

5. pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP (AAV8)

   Viral Prep

   #137140-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP (#137140). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2(E123T/T159C)-EYFP (inhibited in presence of Flp) for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   nEF

   Tags

   EYFP (Cre-dependent)

   Available since

   May 6, 2021

   Availability

   Academic Institutions and Nonprofits only

6. pAAV-nEF-Con/Foff 2.0-ChR2-mCherry (AAV8)

   Viral Prep

   #137143-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-mCherry (#137143). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-mCherry plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-mCherry for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   nEF

   Tags

   mCherry (Cre-dependent)

   Available since

   Feb. 25, 2021

   Availability

   Academic Institutions and Nonprofits only

7. pAAV-nEF-Con/Fon/Von eYFP (AAV Retrograde)

   Viral Prep

   #137164-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from pAAV-nEF-Con/Fon/Von eYFP (#137164). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon/Von eYFP plasmid DNA. nEF-driven, Cre, Flp and VCre-dependent expression of EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   INTRSECT 2.0 Project, Karl Deisseroth

   Article

   Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

   Promoter

   nEF

   Tags

   EYFP (Cre, Flp and VCre-dependent)

   Available since

   Nov. 12, 2020

   Availability

   Academic Institutions and Nonprofits only

8. pX600-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA (AAV6)

   Viral Prep

   #61592-AAV6

   Purpose

   Ready-to-use AAV6 particles produced from pX600-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA (#61592). In addition to the viral particles, you will also receive purified pX600-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA plasmid DNA. CMV-driven expression of SaCas9. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Feng Zhang

   Article

   Ran et al Nature. 2015 Apr 1. doi: 10.1038/nature1

   Promoter

   Tags

   None

   Available since

   July 16, 2025

   Availability

   Academic Institutions and Nonprofits only

9. pAAV-flex-taCasp3-TEVp (AAV5)

   Viral Prep

   #45580-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Jim Wells, Nirao Shah

   Article

   Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

   Promoter

   EF1a

   Tags

   None

   Available since

   Sept. 25, 2020

   Availability

   Academic Institutions and Nonprofits only

10. pAAV-Ef1a-DIO-PPO-Venus (AAV9)

    Viral Prep

    #139505-AAV9

    Purpose

    Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Michael Bruchas

    Article

    Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

    Promoter

    EF1a

    Tags

    Venus (Cre-dependent)

    Available since

    Oct. 28, 2021

    Availability

    Academic Institutions and Nonprofits only

11. pAAV-CAG-DIO-PPO-Venus (AAV5)

    Viral Prep

    #139504-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-CAG-DIO-PPO-Venus (#139504). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-PPO-Venus plasmid DNA. CAG-driven, Cre-dependent expression of Venus-tagged parapinopsin. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Michael Bruchas

    Article

    Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

    Promoter

    CAG

    Tags

    Venus

    Available since

    April 10, 2024

    Availability

    Academic Institutions and Nonprofits only

12. pAAV-Ef1a-DIO-PPO-Venus (AAV8)

    Viral Prep

    #139505-AAV8

    Purpose

    Ready-to-use AAV8 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Michael Bruchas

    Article

    Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

    Promoter

    EF1a

    Tags

    Venus (Cre-dependent)

    Available since

    Sept. 27, 2023

    Availability

    Academic Institutions and Nonprofits only

13. pAAV_hSyn-PdCO-mScarlet-WPRE (AAV5)

    Viral Prep

    #198510-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-mScarlet-WPRE (#198510). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

    Promoter

    Syn

    Tags

    mScarlet

    Available since

    Sept. 27, 2024

    Availability

    Academic Institutions and Nonprofits only

14. pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (AAV5)

    Viral Prep

    #125713-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (#125713). In addition to the viral particles, you will also receive purified pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

    Promoter

    Syn

    Tags

    mScarlet (Cre-dependent)

    Available since

    Sept. 13, 2021

    Availability

    Academic Institutions and Nonprofits only

15. pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (AAV1)

    Viral Prep

    #125713-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE (#125713). In addition to the viral particles, you will also receive purified pAAV-hSyn1-SIO-eOPN3-mScarlet-WPRE plasmid DNA. Synapsin-driven, Cre-dependent expression of mosquito OPN3 rhodopsin in-frame with mScarlet.These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

    Promoter

    Syn

    Tags

    mScarlet (Cre-dependent)

    Available since

    Sept. 20, 2019

    Availability

    Academic Institutions and Nonprofits only

16. pAAV_hSyn-PdCO-mScarlet-WPRE (AAV1)

    Viral Prep

    #198510-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV_hSyn-PdCO-mScarlet-WPRE (#198510). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

    Promoter

    Syn

    Tags

    mScarlet

    Available since

    Jan. 27, 2025

    Availability

    Academic Institutions and Nonprofits only

17. pAAV_hSyn-PdCO-EGFP-WPRE (AAV1)

    Viral Prep

    #198513-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

    Promoter

    Syn

    Tags

    EGFP

    Available since

    April 10, 2024

    Availability

    Academic Institutions and Nonprofits only

18. pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (AAV5)

    Viral Prep

    #125712-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

    Promoter

    short version of αCamKinase II promoter (0.4kb)

    Tags

    mScarlet

    Available since

    June 26, 2024

    Availability

    Academic Institutions and Nonprofits only

19. pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (AAV1)

    Viral Prep

    #125712-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

    Promoter

    short version of αCamKinase II promoter (0.4kb)

    Tags

    mScarlet

    Available since

    June 26, 2024

    Availability

    Academic Institutions and Nonprofits only

20. pAAV_hSyn-PdCO-EGFP-WPRE (AAV5)

    Viral Prep

    #198513-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

    Promoter

    Syn

    Tags

    EGFP

    Available since

    April 10, 2024

    Availability

    Academic Institutions and Nonprofits only